MISTY CAGLE: Open Payments
NPI 1891941241 · HATTIESBURG, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$301 in 16 payments from 9 companies in 2025. Trend: 2023 $523 · 2024 $250 · 2025 $301
Food & beverage: $301
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 4 | $76 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $49 |
| Novo Nordisk Inc | 2 | $45 |
| Amgen Inc. | 2 | $41 |
| Abbott Laboratories | 1 | $22 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Exact Sciences Corporation | 1 | $18 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $17 |
| AstraZeneca Pharmaceuticals LP | 1 | $14 |
Products named: QULIPTA, CAPLYTA, EVENITY, Saxenda, FREESTYLE LIBRE 3, TRINTELLIX, The Cologuard Plus Collection Kit, JARDIANCE.
Industry payments across MS — which companies pay providers there.
